Rezlidhia™ (olutasidenib)
for Leukemia

Rezlidhia (olutasidenib) is prescribed to treat adults with acute myeloid leukemia (AML) caused by an IDH1 gene mutation, which blocks healthy blood cell maturation. It’s an IDH1 inhibitor, working by stopping the abnormal IDH1 protein activity, thus promoting the development of healthy, mature blood cells in the bone marrow.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia